Effects of Psilocybin in Concussion Headache

This double-blind cross-over trial (n=24) investigates the effect of repeated doses of psilocybin (2x) at varying doses of psilocybin (1 or 10mg) on concussion headache.

Topic Headache Disorders Traumatic Brain Injury Pain

Compound Psilocybin

Country United States of America

Visit trial

Status Recruiting

Results Published No

Start date 28 March 2019

End date 15 July 2023

Chance of happening 100%

Phase Phase I

Design Blinded

Type Interventional

Generation First

Participants 24

Sex All

Age 21- 65

Therapy No

Trial Details

The purpose of this study is to investigate the effects of oral psilocybin in post-traumatic headache. Subjects will be randomized to receive placebo, low dose psilocybin, or high dose psilocybin on two separate test days approximately 14 days apart. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. Blood samples will be drawn at various timepoints to measure levels of inflammatory peptides.

NCT Number NCT03806985

Sponsors & Collaborators

Yale University
The Yale Psychedelic Science Group was established in 2016.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.